Bausch Health Companies Inc. (TSE:BHC - Free Report) - Investment analysts at Zacks Research lifted their FY2024 earnings per share (EPS) estimates for Bausch Health Companies in a research report issued on Tuesday, December 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $5.33 for the year, up from their prior forecast of $5.21. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2024 earnings at $1.60 EPS, Q1 2025 earnings at $1.22 EPS, Q2 2025 earnings at $1.47 EPS, Q3 2025 earnings at $1.65 EPS, FY2025 earnings at $6.13 EPS, Q1 2026 earnings at $1.56 EPS, Q2 2026 earnings at $1.63 EPS, Q3 2026 earnings at $1.96 EPS and FY2026 earnings at $7.23 EPS.
Bausch Health Companies (TSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported C$1.53 EPS for the quarter, topping analysts' consensus estimates of C$1.43 by C$0.10. The business had revenue of C$3.42 billion during the quarter, compared to the consensus estimate of C$3.36 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%.
Separately, Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th.
Get Our Latest Report on BHC
Bausch Health Companies Trading Up 0.5 %
TSE BHC traded up C$0.05 during mid-day trading on Thursday, reaching C$10.64. 171,332 shares of the stock were exchanged, compared to its average volume of 367,516. The stock has a market capitalization of C$3.91 billion, a PE ratio of -6.08, a PEG ratio of 0.21 and a beta of 0.77. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. Bausch Health Companies has a 1-year low of C$5.45 and a 1-year high of C$15.43. The business's fifty day simple moving average is C$11.68 and its 200 day simple moving average is C$9.93.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
